{"id":"escitalopram-oxylate","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"5-10","effect":"Somnolence"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Dry mouth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As the active S-enantiomer of citalopram, escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT), preventing the reabsorption of serotonin from the synapse. This increases serotonin concentration and enhances neurotransmission, which is thought to improve mood and reduce anxiety symptoms. The oxalate salt formulation provides improved bioavailability and stability compared to the racemic mixture.","oneSentence":"Escitalopram oxalate selectively inhibits the reuptake of serotonin at the neuronal membrane, increasing serotonin availability in the synaptic cleft.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:44:21.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT00329446","phase":"PHASE3","title":"Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Generalized Anxiety Disorder","enrollment":800}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIARRHOEA"},{"count":1,"reaction":"ABDOMINAL TENDERNESS"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"ARTERIOSCLEROSIS"},{"count":1,"reaction":"BACK DISORDER"},{"count":1,"reaction":"BONE CANCER"},{"count":1,"reaction":"CARDIAC ARREST"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CRYING"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Escitalopram oxylate","genericName":"Escitalopram oxylate","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Escitalopram oxalate selectively inhibits the reuptake of serotonin at the neuronal membrane, increasing serotonin availability in the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}